Approval · Notice of Compliance 31088 · 2023
WEGOVY: Notice of Compliance 31088
Issued June 29, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31088
- Date
- June 29, 2023
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Indication expansion Wegovy (semaglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: - Pediatric patients aged 12 to less than 18 years: - with an initial BMI at the 95th percentile or greater for age and sex (obesity; see Error! Reference source not found.), and - a body weight above 60 kg (132 lbs), and - an inadequate response to reduced calorie diet and physical activity alone.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| WEGOVY | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 0.5 MG per ML
- SEMAGLUTIDE 1 MG per ML
- SEMAGLUTIDE 2 MG per ML
- SEMAGLUTIDE 2.27 MG per ML
- SEMAGLUTIDE 3.2 MG per ML
- SEMAGLUTIDE 0.68 MG per ML
- SEMAGLUTIDE 1.34 MG per ML